# Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer

Source: https://onco.cc/trials/nct07132008/  
OnCo record `nct07132008` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of tislelizumab, fOLFOX (5-FU, leucovorin, oxaliplatin) and capecitabine in colorectal cancer, run by First Affiliated Hospital of Guangxi Medical University, not yet recruiting.

## Summary

Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer is a phase 3, randomised interventional study registered as NCT07132008 by First Affiliated Hospital of Guangxi Medical University, with a registry enrolment figure of 94 participants, started 2025-10-01 and due to reach its primary completion in 2027-09-30. Interventions recorded: Tislelizumab; Oxaliplatin; Capecitabine. Conditions listed: Colonic Neoplasms; Neoadjuvant Therapy; Immune Checkpoint Inhibitors. Primary outcome: Pathological complete response (pCR). Colorectal eligibility wording from the registry: "* Pathologically diagnosed MSS ((confirmed by microsatellite stable detection or next-generation target sequencing) or (confirmed by immunohistochemistry)) colon adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07132008
- Phase: 3
- Setting: Prospective, Multicenter, Randomized Trial of Neoadjuvant Capecitabine and Oxaliplatin (CAPOX) Plus Tislelizumab Versus CAPOX in Microsatellite Stable High-risk Locally Advanced Colon Cancer
- Sponsor: First Affiliated Hospital of Guangxi Medical University
- Enrolled: 94

## Sources

- ClinicalTrials.gov NCT07132008: https://clinicaltrials.gov/study/NCT07132008

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07132008.json